Drug
Dianhydrogalactitol clinical trials
- studies test it
- 6
- open now
- 1
- in phase 3
- 2
- first study started
- 2011
Keep track of what changes. Save the Dianhydrogalactitol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2017 | 3 |
| 2019 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 1
Kintara Therapeutics, Inc. (3) · DelMar Pharmaceuticals, Inc. (2) · Global Coalition for Adaptive Research (1)
Often tested with
Tested in the same studies.
Regorafenib (1) · GDC-0084 (1) · TSP-1 Activator VT1021 (1) · Troriluzole (1) · Pegargiminase (1) · AZD1390 (1) · Tinostamustine (1)
Studies
Open first, then newest update. How each study uses Dianhydrogalactitol is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as VAL-083
- Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT ExpressionCompletedPhase 2Kintara Therapeutics, Inc.NCT03050736Written as VAL-083 (Dianhydrogalactitol)
- VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBMTerminatedPhase 3DelMar Pharmaceuticals, Inc.NCT03149575Written as VAL-083, Dianhydrogalactitol
- Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent SettingCompletedPhase 2Kintara Therapeutics, Inc.NCT02717962Written as VAL-083, Dianhydrogalactitol
- Safety Study of VAL-083 in Patients With Recurrent Malignant GliomaCompletedPhase 1/2Kintara Therapeutics, Inc.NCT01478178Written as VAL-083 (Dianhydrogalactitol)
- A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian CancerWithdrawnPhase 1/2DelMar Pharmaceuticals, Inc.NCT03281681Written as VAL-083, Dianhydrogalactitol
Codes
What other systems call Dianhydrogalactitol · ClinicalTrials.gg INT007330
- MeSH (NLM) D003961DianhydrogalactitolConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4S465RYF7MDIANHYDROGALACTITOLConfirmed FDA, NLM, Wikidata
- Wikidata Q27260414dianhydrogalactitolConfirmed FDA, NLM, Wikidata
- DrugBank DB12873One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D003961 | Dianhydrogalactitol | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4S465RYF7M | DIANHYDROGALACTITOL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27260414 | dianhydrogalactitol | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB12873 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.